Portfolio companies news

27 February 2017

Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has initiated a strategic realignment of its research and development resources from its pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (“wet AMD”) toward its ongoing clinical development program for the treatment of diabetic macular edema (“DME”) assessing ZuprataTM, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide.

17 February 2017

Raikhana Shangareyeva becomes Vice President, Production, at NovaMedica

Raikhana Shangareyeva, who was previously in charge of manufacturing at an enterprise of JSC R-Pharm, has been appointed Vice President, Production, of the pharmaceutical company NovaMedica. She will be trusted with making NovaMedica’s production facility operational and with organizing workflow processes there.

16 February 2017

Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“SAPPHIRE”) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with EYLEA® (aflibercept) for the treatment of macular edema associated with retinal vein occlusion (“RVO”).

14 February 2017

Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a  mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. AS is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments and epilepsy. 

09 February 2017

Syndax Appoints Richard P. Shea as Chief Financial Officer

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Shea is stepping down from his position on the Syndax Board of Directors and is joining the Company as Chief Financial Officer.

01 February 2017

Marinus Appoints Michael R. Dougherty to its Board of Directors

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.

01 February 2017

Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

Yahoo Finance

The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

31 January 2017

Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board.

24 January 2017

Atlas Genetics Raises $35m in Series D Fundraising

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

23 January 2017

Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business overview to outline the clinical status of its CNS-selective GABA_A modulator, ganaxolone, and an overview of near-term value-creating milestones expected in 2017.